Plerixafor
- Generic Name
- Plerixafor
- Brand Names
- Mozobil, Plerixafor Accord
- Drug Type
- Small Molecule
- Chemical Formula
- C28H54N8
- CAS Number
- 110078-46-1
- Unique Ingredient Identifier
- S915P5499N
- Background
Plerixafor is a small-molecule inhibitor of C-X-C chemokine receptor type 4 (CXCR4) that acts as a hematopoietic stem cell mobilizer. It is used to stimulate the release of stem cells from the bone marrow into the blood in patients with non-Hodgkin's lymphoma (NHL) and multiple myeloma to stimulate their immune system. These stem cells are then collected and...
- Indication
Plerixafor is indicated in combination with granulocyte-colony stimulating factor (G-CSF) to mobilize hematopoietic stem cells (HSCs) to the peripheral blood for collection and subsequent autologous transplantation in patients with non-Hodgkin’s lymphoma or multiple myeloma.
- Associated Conditions
- -
- Associated Therapies
- Mobilization of hematopoietic stem cells
Study of AMD3100 (Plerixafor) and Rituximab in Patients With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
- Conditions
- Interventions
- First Posted Date
- 2008-06-10
- Last Posted Date
- 2015-03-20
- Lead Sponsor
- Genzyme, a Sanofi Company
- Target Recruit Count
- 24
- Registration Number
- NCT00694590
- Locations
- 🇺🇸
UTMD Anderson Cancer Center, Houston, Texas, United States
🇺🇸Ohio State University Comprehensive Cancer Center, Columbus, Ohio, United States
🇺🇸UCSD Moores Cancer Center, La Jolla, California, United States
O6-Benzylguanine-Mediated Tumor Sensitization With Chemoprotected Autologous Stem Cell in Treating Patients With Malignant Gliomas
- Conditions
- Interventions
- Radiation: 3-Dimensional Conformal Radiation TherapyProcedure: Autologous Hematopoietic Stem Cell TransplantationDrug: CarmustineBiological: FilgrastimProcedure: In Vitro-Treated Peripheral Blood Stem Cell TransplantationRadiation: Intensity-Modulated Radiation TherapyOther: Laboratory Biomarker AnalysisDrug: O6-BenzylguanineDrug: PlerixaforRadiation: Proton Beam Radiation TherapyDrug: Temozolomide
- First Posted Date
- 2008-04-30
- Last Posted Date
- 2022-05-18
- Lead Sponsor
- Fred Hutchinson Cancer Center
- Target Recruit Count
- 12
- Registration Number
- NCT00669669
- Locations
- 🇺🇸
Fred Hutch/University of Washington Cancer Consortium, Seattle, Washington, United States
Safety, Pharmacokinetics (PK), And Hematological Activity Of AMD3100 (Plerixafor) In Subjects With Renal Impairment
- First Posted Date
- 2007-03-08
- Last Posted Date
- 2014-03-13
- Lead Sponsor
- Genzyme, a Sanofi Company
- Target Recruit Count
- 23
- Registration Number
- NCT00445302
- Locations
- 🇺🇸
Apex Research of Riverside, Santa Ana, California, United States
🇺🇸Prism Research, 1000 Westgate Dr. suite 149, St. Paul, Minnesota, United States
🇺🇸Creighton University Medical Center, Omaha, Nebraska, United States
Treatment With AMD3100 (Plerixafor) in MM Patients to Mobilize PBCs For Collection and for Transplantation
- First Posted Date
- 2006-11-06
- Last Posted Date
- 2014-03-13
- Lead Sponsor
- Genzyme, a Sanofi Company
- Target Recruit Count
- 9
- Registration Number
- NCT00396383
- Locations
- 🇺🇸
Memorial Sloan-Kettering Cancer Center, New York, New York, United States
🇺🇸Thomas Jefferson University, Philadelphia, Pennsylvania, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.